| Literature DB >> 24836863 |
Nuria García Segarra1, Ivan Gautschi2, Laureane Mittaz-Crettol3, Christine Kallay Zetchi4, Lama Al-Qusairi2, Miguel Xavier Van Bemmelen2, Philippe Maeder5, Luisa Bonafé3, Laurent Schild2, Eliane Roulet-Perez4.
Abstract
Mutations in the CACNA1A gene, encoding the α1 subunit of the voltage-gated calcium channel Ca(V)2.1 (P/Q-type), have been associated with three neurological phenotypes: familial and sporadic hemiplegic migraine type 1 (FHM1, SHM1), episodic ataxia type 2 (EA2), and spinocerebellar ataxia type 6 (SCA6). We report a child with congenital ataxia, abnormal eye movements and developmental delay who presented severe attacks of hemiplegic migraine triggered by minor head traumas and associated with hemispheric swelling and seizures. Progressive cerebellar atrophy was also observed. Remission of the attacks was obtained with acetazolamide. A de novo 3 bp deletion was found in heterozygosity causing loss of a phenylalanine residue at position 1502, in one of the critical transmembrane domains of the protein contributing to the inner part of the pore. We characterized the electrophysiology of this mutant in a Xenopus oocyte in vitro system and showed that it causes gain of function of the channel. The mutant Ca(V)2.1 activates at lower voltage threshold than the wild type. These findings provide further evidence of this molecular mechanism as causative of FHM1 and expand the phenotypic spectrum of CACNA1A mutations with a child exhibiting severe SHM1 and non-episodic ataxia of congenital onset.Entities:
Keywords: Acetazolamide response; Congenital ataxia; Developmental delay; Gain of function; Novel CACNA1A mutation; Severe SHM1
Mesh:
Substances:
Year: 2014 PMID: 24836863 DOI: 10.1016/j.jns.2014.04.027
Source DB: PubMed Journal: J Neurol Sci ISSN: 0022-510X Impact factor: 3.181